Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressivediseasewithamediansurvivalof 3–5 years (1, 2). The approval of nintedanib and pirfenidone by regulatory agencies worldwide has dramatically altered the landscape for testing new drugs for IPF treatment. These drugs slowed the progression of the FVC decline observed in IPF cohorts in phase III randomized, double-blind, placebo-controlled trials (3, 4).
Lingua originale | English |
---|---|
pagine (da-a) | 133-139 |
Numero di pagine | 7 |
Rivista | American Journal of Respiratory and Critical Care Medicine |
Volume | 200 |
DOI | |
Stato di pubblicazione | Pubblicato - 2019 |
Keywords
- Anti-Inflammatory Agents, Non-Steroidal
- Clinical Trials as Topic
- Drug Approval
- Drug Development
- Drug Interactions
- Drug Therapy, Combination
- Humans
- Idiopathic Pulmonary Fibrosis
- Indoles
- Patient Outcome Assessment
- Protein Kinase Inhibitors
- Pyridones
- Quality of Life
- Standard of Care
- Vital Capacity
- Walk Test